Fewer than one in 10 people eligible to benefit from obesity jabs like Wegovy are able to get them, caution the WHO as it publishes its inaugural guidance on the medications.
With in excess of 1,000,000,000 individuals worldwide now classified as obese, it is advocating for more widespread and fairer availability to this class of drugs.
Based on projections, in excess of 2,000,000,000 could be living with obesity by 2030 if no action is taken.
"Our new guidance affirms that obesity is a lifelong illness that can be addressed with holistic and ongoing support," said WHO director-general Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and distribution challenges are key barriers to universal access to the jabs that can assist patients in reducing significant body mass, notes the agency.
Skinny Jab Shortage
Even under the present most optimistic outlook, the supply of GLP-1 therapies might only reach around 100 million people – fewer than 10% of eligible patients, as stated by the health organization.
The recommendation encourages nations and manufacturers to expand access, through strategies including patent sharing.
A patent on the active ingredient – the main component of Novo Nordisk's Wegovy – is set to lapse in multiple countries in 2026.
The Way Weight-Loss Drugs Work
The injections mimick a biological compound to slow digestion, reduce hunger and boost feelings of fullness so users reduce food intake.
People typically see weight reduction in the initial weeks of beginning the weekly injections.
Studies indicates users may see weight return within a year of discontinuing the drug, because their typical hunger come back.
To be above a healthy weight elevates your likelihood for developing diseases, like diabetes, heart disease, brain attack, and certain malignancies.
Obesity concerns individuals in countries worldwide and was associated with millions of deaths worldwide in 2024, as per the health agency.
